aTyr Pharma (NASDAQ:LIFE) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report issued on Thursday.
According to Zacks, “aTyr Pharma, Inc. is a bio-therapeutics company. The Company is involved in the discovery and development of medicines for severe, rare diseases of physiological modulators. aTyr Pharma, Inc. is a based in SAN DIEGO, United States. “
Other equities research analysts have also issued reports about the stock. ValuEngine lowered shares of aTyr Pharma from a “sell” rating to a “strong sell” rating in a report on Friday, December 1st. JPMorgan Chase & Co. lowered shares of aTyr Pharma from a “neutral” rating to an “underweight” rating in a report on Wednesday, February 14th. Two investment analysts have rated the stock with a sell rating, three have assigned a hold rating and one has issued a buy rating to the company. The stock currently has an average rating of “Hold” and an average target price of $4.56.
Large investors have recently bought and sold shares of the business. Deutsche Bank AG purchased a new stake in aTyr Pharma in the fourth quarter valued at $199,000. Dimensional Fund Advisors LP boosted its holdings in aTyr Pharma by 44.1% in the third quarter. Dimensional Fund Advisors LP now owns 83,848 shares of the biotechnology company’s stock valued at $423,000 after purchasing an additional 25,676 shares during the last quarter. Victory Capital Management Inc. purchased a new stake in aTyr Pharma in the third quarter valued at $455,000. Artal Group S.A. purchased a new stake in shares of aTyr Pharma during the 3rd quarter worth about $1,263,000. Finally, Renaissance Technologies LLC boosted its stake in shares of aTyr Pharma by 143.2% during the 4th quarter. Renaissance Technologies LLC now owns 279,400 shares of the biotechnology company’s stock worth $978,000 after acquiring an additional 164,500 shares in the last quarter. 60.06% of the stock is currently owned by institutional investors.
ILLEGAL ACTIVITY WARNING: “aTyr Pharma (LIFE) Downgraded by Zacks Investment Research to Hold” was originally posted by Ticker Report and is owned by of Ticker Report. If you are viewing this report on another publication, it was stolen and republished in violation of U.S. and international trademark & copyright laws. The correct version of this report can be read at https://www.tickerreport.com/banking-finance/3229312/atyr-pharma-life-downgraded-by-zacks-investment-research-to-hold.html.
aTyr Pharma Company Profile
aTyr Pharma, Inc is a clinical-stage biotherapeutics company. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its Physiocrine biology, a discovered set of physiological modulators. The Company focuses on the development of Physiocrine-based therapeutics for the treatment of rare diseases, including facioscapulohumeral muscular dystrophy (FSHD) and limb-girdle muscular dystrophy (LGMD) 2B.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for aTyr Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for aTyr Pharma and related companies with MarketBeat.com's FREE daily email newsletter.